| Display title | Chemistry:Retapamulin |
| Default sort key | Retapamulin |
| Page length (in bytes) | 4,989 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 496679 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Steve Marsio |
| Date of page creation | 12:30, 26 June 2023 |
| Latest editor | imported>Steve Marsio |
| Date of latest edit | 12:30, 26 June 2023 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Retapamulin is a topical antibiotic developed by GlaxoSmithKline. It is the first drug in the new class of pleuromutilin antibiotics to be approved for human use. It is marketed as an ointment under the brand names Altabax and Altargo.
Retapamulin was approved by the United States Food and Drug Administration... |
